Personally I have no concern about "time running out". I have been buying here and there for years in stocks that have historically had the same FOMO emotion attached to them - it's nonsense I think.
Anyway, re "The fact that MSB does not have a large number of shares on issue, compared with many biotechs, is a plus"
Can you explain why you think this and also why a small number of issued stock reduces the pain of dilution?
@travelightor produced an excellent post to highlight what I think is a common misunderstanding people have with this issue.
MSB Price at posting:
$2.39 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)